Suneel D Mundle

Summary

Publications

  1. ncbi Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes
    Gurveen Saberwal
    MDS Center and Section of Myeloid Diseases, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, IL 60612, USA
    J Hematother Stem Cell Res 12:443-50. 2003
  2. ncbi Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow
    Gurveen Saberwal
    MDS Center and Section of Myeloid Diseases, Rush University, Chicago, Illinois, USA
    Int J Hematol 80:146-54. 2004
  3. ncbi Evolving intricacies and implications of E2F1 regulation
    Suneel D Mundle
    Rush Cancer, Institute Section of Myeloid Diseases and MDS Center, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, Illinois 60612, USA
    FASEB J 17:569-74. 2003
  4. ncbi Lingering biologic dilemmas about the status of the progenitor cells in myelodysplasia
    Suneel D Mundle
    Department of Biochemistry, Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    Arch Med Res 34:515-9. 2003
  5. ncbi Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes
    Suneel D Mundle
    OrthoBiotech Clinical Affairs LLC, Bridgewater, NJ, USA
    Future Oncol 3:397-403. 2007
  6. ncbi An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach
    Suneel Mundle
    Medical Affairs, Centocor OrthoBiotech Services, LLC, Horsham, Pennsylvania, USA
    Cancer 115:706-15. 2009
  7. ncbi Advances in erythropoietic growth factor therapy for myelodysplastic syndromes
    Suneel D Mundle
    Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
    Expert Opin Biol Ther 6:1099-104. 2006
  8. ncbi Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes
    Poluru L Reddy
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612 3515, USA
    Br J Haematol 116:564-75. 2002
  9. ncbi Par-4: a common facilitator/enhancer of extrinsic and intrinsic pathways of apoptosis
    Suneel D Mundle
    Leuk Res 30:515-7. 2006

Collaborators

Detail Information

Publications9

  1. ncbi Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes
    Gurveen Saberwal
    MDS Center and Section of Myeloid Diseases, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, IL 60612, USA
    J Hematother Stem Cell Res 12:443-50. 2003
    ..008). Thus, it is possible that in a subset of MDS patients, apoptotic death of bone marrow cells may involve Cyclin D1/E2F1 pathway...
  2. ncbi Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow
    Gurveen Saberwal
    MDS Center and Section of Myeloid Diseases, Rush University, Chicago, Illinois, USA
    Int J Hematol 80:146-54. 2004
    ..Hence, the observation in MDS of increased E2F1 activity in the presence of normal Rb levels is novel and unique, and E2F1 activity in association with apoptosis in S-phase cells may thus have significant therapeutic implications...
  3. ncbi Evolving intricacies and implications of E2F1 regulation
    Suneel D Mundle
    Rush Cancer, Institute Section of Myeloid Diseases and MDS Center, Rush Presbyterian St Luke s Medical Center, Rush University, Chicago, Illinois 60612, USA
    FASEB J 17:569-74. 2003
    ..The present review is intended to provide a perspective on the diversity of biochemical mechanisms underlying abnormal E2F expression and activity, understanding of which may have significant clinical implications...
  4. ncbi Lingering biologic dilemmas about the status of the progenitor cells in myelodysplasia
    Suneel D Mundle
    Department of Biochemistry, Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    Arch Med Res 34:515-9. 2003
    ....
  5. ncbi Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes
    Suneel D Mundle
    OrthoBiotech Clinical Affairs LLC, Bridgewater, NJ, USA
    Future Oncol 3:397-403. 2007
    ..The present report provides a detailed comparative profile of long-term PRBC transfusions and the balance of clinical benefits versus risks associated with ESA therapy for MDS...
  6. ncbi An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach
    Suneel Mundle
    Medical Affairs, Centocor OrthoBiotech Services, LLC, Horsham, Pennsylvania, USA
    Cancer 115:706-15. 2009
    ..Over the years, different therapeutic strategies have been adopted to optimize the clinical benefits of EPO in this setting...
  7. ncbi Advances in erythropoietic growth factor therapy for myelodysplastic syndromes
    Suneel D Mundle
    Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA
    Expert Opin Biol Ther 6:1099-104. 2006
    ..This review discusses the evolution of therapeutic strategies incorporating EPO for the treatment of MDS...
  8. ncbi Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes
    Poluru L Reddy
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612 3515, USA
    Br J Haematol 116:564-75. 2002
    ..These results suggest a role for mt-DNA mutations in the excessive apoptosis and resulting cytopenias of MDS patients...
  9. ncbi Par-4: a common facilitator/enhancer of extrinsic and intrinsic pathways of apoptosis
    Suneel D Mundle
    Leuk Res 30:515-7. 2006
    ..Further understanding of Par-4 biology will have significant clinical implications especially in overcoming drug resistance phenomenon in cancer...